These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 26494003)

  • 1. Epigenetic-based therapy: From single- to multi-target approaches.
    Benedetti R; Conte M; Iside C; Altucci L
    Int J Biochem Cell Biol; 2015 Dec; 69():121-31. PubMed ID: 26494003
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The potential of DNA modifications as biomarkers and therapeutic targets in oncology.
    Jankowska AM; Millward CL; Caldwell CW
    Expert Rev Mol Diagn; 2015; 15(10):1325-37. PubMed ID: 26394702
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Epigenetics and oncology.
    Mummaneni P; Shord SS
    Pharmacotherapy; 2014 May; 34(5):495-505. PubMed ID: 24619798
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Epigenetic alterations in cancer and personalized cancer treatment.
    Miozzo M; Vaira V; Sirchia SM
    Future Oncol; 2015; 11(2):333-48. PubMed ID: 25591842
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Epigenetic opportunities and challenges in cancer.
    Best JD; Carey N
    Drug Discov Today; 2010 Jan; 15(1-2):65-70. PubMed ID: 19897050
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting DNA methylation with small molecules: what's next?
    Erdmann A; Halby L; Fahy J; Arimondo PB
    J Med Chem; 2015 Mar; 58(6):2569-83. PubMed ID: 25406944
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel approaches on epigenetics.
    Papait R; Monti E; Bonapace IM
    Curr Opin Drug Discov Devel; 2009 Mar; 12(2):264-75. PubMed ID: 19333872
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Epigenetic perspectives on cancer chemotherapy response.
    Liu MZ; McLeod HL; He FZ; Chen XP; Zhou HH; Shu Y; Zhang W
    Pharmacogenomics; 2014 Apr; 15(5):699-715. PubMed ID: 24798726
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synthetic lethal vulnerabilities of cancer.
    Fece de la Cruz F; Gapp BV; Nijman SM
    Annu Rev Pharmacol Toxicol; 2015; 55():513-31. PubMed ID: 25340932
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Epidrugs: targeting epigenetic marks in cancer treatment.
    Miranda Furtado CL; Dos Santos Luciano MC; Silva Santos RD; Furtado GP; Moraes MO; Pessoa C
    Epigenetics; 2019 Dec; 14(12):1164-1176. PubMed ID: 31282279
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Epigenetic drugs against cancer: an evolving landscape.
    Di Costanzo A; Del Gaudio N; Migliaccio A; Altucci L
    Arch Toxicol; 2014 Sep; 88(9):1651-68. PubMed ID: 25085708
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mechanisms of acquired resistance to targeted cancer therapies.
    Lackner MR; Wilson TR; Settleman J
    Future Oncol; 2012 Aug; 8(8):999-1014. PubMed ID: 22894672
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Epi-drugs to fight cancer: from chemistry to cancer treatment, the road ahead.
    Mai A; Altucci L
    Int J Biochem Cell Biol; 2009 Jan; 41(1):199-213. PubMed ID: 18790076
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Epigenetic mechanisms in tumorigenesis, tumor cell heterogeneity and drug resistance.
    Wilting RH; Dannenberg JH
    Drug Resist Updat; 2012; 15(1-2):21-38. PubMed ID: 22356866
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Network-Oriented Approaches to Anticancer Drug Response.
    Lecca P; Re A
    Methods Mol Biol; 2017; 1513():101-117. PubMed ID: 27807833
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Epigenetic drugs as pleiotropic agents in cancer treatment: biomolecular aspects and clinical applications.
    Sigalotti L; Fratta E; Coral S; Cortini E; Covre A; Nicolay HJ; Anzalone L; Pezzani L; Di Giacomo AM; Fonsatti E; Colizzi F; Altomonte M; Calabrò L; Maio M
    J Cell Physiol; 2007 Aug; 212(2):330-44. PubMed ID: 17458893
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Epigenetic polypharmacology: A new frontier for epi-drug discovery.
    Tomaselli D; Lucidi A; Rotili D; Mai A
    Med Res Rev; 2020 Jan; 40(1):190-244. PubMed ID: 31218726
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Epigenetic cancer therapy makes headway.
    Mack GS
    J Natl Cancer Inst; 2006 Oct; 98(20):1443-4. PubMed ID: 17047192
    [No Abstract]   [Full Text] [Related]  

  • 19. Editorial overview: cancer: from target discovery to targeted therapy: the risky business of target validation.
    Cruzalegui F
    Curr Opin Pharmacol; 2014 Aug; 17():iv-vi. PubMed ID: 25220882
    [No Abstract]   [Full Text] [Related]  

  • 20. Epigenetic biomarkers for human cancer: the time is now.
    Mulero-Navarro S; Esteller M
    Crit Rev Oncol Hematol; 2008 Oct; 68(1):1-11. PubMed ID: 18430583
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.